Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab

Next Previous
Trial Profile

Phase 1/2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; BI 1206 (Primary) ; BI 1206 (Primary) ; Rituximab
  • Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors BioInvent International

Most Recent Events

  • 08 Dec 2025 According to a BioInvent International media release, company announced the presentation of new data from the safety run-in portion of its ongoing trial evaluating BI-1206, in combination with rituximab and Calquence (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL) at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
  • 08 Dec 2025 Results presented in a BioInvent International media release
  • 08 Dec 2025 According to BioInvent International media release, company announced the presentation of new data from this study at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top